Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 12/15 05:36:56 pm
73.55 EUR   -0.30%
12/15DJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
12/15 SANOFI : FDA lifts clinical hold on fitusiran
12/15 SANOFI : FDA lifts clinical hold on fitusiran
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
12/11/2017 12/12/2017 12/13/2017 12/14/2017 12/15/2017 Date
73.58(c) 75.03(c) 74.66(c) 73.77(c) 73.55(c) Last
1 958 420 2 708 681 3 327 280 2 008 093 4 378 223 Volume
+0.55% +1.97% -0.49% -1.19% -0.30% Change
More quotes
Financials (€)
Sales 2017 35 834 M
EBIT 2017 9 337 M
Net income 2017 8 158 M
Debt 2017 4 979 M
Yield 2017 4,11%
Sales 2018 36 135 M
EBIT 2018 9 344 M
Net income 2018 5 718 M
Debt 2018 3 990 M
Yield 2018 4,20%
P/E ratio 2017 11,52
P/E ratio 2018 15,97
EV / Sales2017 2,73x
EV / Sales2018 2,68x
Capitalization 92 904 M
More Financials
Company
Sanofi engages in the research, production and distribution of pharmaceutical products.It operates through the following business segments: Pharmaceuticals, Human Vaccines, and Animal Health.The Pharmaceuticals segment includes research, development, production and sales activities relating to... 
Sector
Pharmaceuticals
Calendar
12/15 | 02:30pmAnalyst Day - Q&A
More about the company
Surperformance© ratings of Sanofi
Trading Rating : Investor Rating :
More Ratings
Latest news on SANOFI
12/15 SANOFI : Aquino not yet off the hook Richard Gordon
12/15DJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
12/15 SANOFI : Solon wants Sanofi, DOH held liable for vaccine mess
12/15 NOBODY KNEW DENGVAXIA POSED RISKS : ex-president Aquino
12/15 SANOFI : Aquino confirms Paris meeting with Sanofi execs over vaccine supply
12/15 SANOFI : FDA lifts clinical hold on fitusiran
12/15 SANOFI : FDA lifts clinical hold on fitusiran
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
12/15 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Topline Pivotal Results..
12/15 REGENERON PHARMACEUTICALS : Collaboration Programs Highlighted During Sanofi Ana..
More news
Sector news : Pharmaceuticals - NEC
11:38a PROCTER & GAMBLE : P&G appoints Peltz to board despite losing proxy battle
11:38a NELSON PELTZ : P&G appoints Peltz to board despite losing proxy battle
12/15 JAZZ PHARMACEUTICALS : Pennsylvania man admits to trading on tips about drug com..
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
12/15DJTEVA PHARMACEUTICAL INDUSTRIES : Generics Giant Cuts Staff by 25% -- WSJ
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on SANOFI 
SANOFI - 11/17
Good timing to go long again
BUY
SANOFI - 08/14
A support level that should be taken advantage of
BUY
More Strategies
News from SeekingAlpha
12/15 BIOTECH FORUM DAILY DIGEST : Impacts Of Tax Reform
12/15 FDA lifts clinical hold on Alnylam's fitusiran; shares up 6% premarket
12/14 Sanofi (SNY) Investor Presentation - Slideshow
12/14 Challenge of two Lantus patents commences
12/14 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 14, 2017
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 84,1 €
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-4.07%109 152
JOHNSON & JOHNSON22.95%382 722
PFIZER12.25%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.3.91%212 270
MERCK AND COMPANY-4.86%153 386